Liposomes to cubosomes: The evolution of lipidic nanocarriers and their cutting-edge biomedical applications

ARINDAM PRAMANIK,Nishtha Attri,Swarnali Das,Jhimli Banerjee,Shazana H. Shamsuddin,Sandeep Kumar Dash

DOI: https://doi.org/10.26434/chemrxiv-2024-w671q

2024-01-31

Abstract:Lipidic nanoparticles have undergone extensive research towards the exploration of their diversely ranging therapeutic applications. Although several liposomal formulations are in the clinics (e.g., DOXIL) for cancer therapy there are many challenges associated with the traditional liposomes. To address these issues, modifications in liposomal structure and further functionalization are desirable, leading to the emergence of solid lipid nanoparticles and the more recent liquid lipid nanoparticles. In this context, ‘cubosomes’, third-generation lipidic nanocarriers, have attracted significant attention due to their numerous advantages, including their porous structure, structural adaptability, high encapsulation efficiency resulting from their extensive internal surface area, enhanced stability, and biocompatibility. Cubosomes offer the potential for both enhanced cellular uptake and controlled release of encapsulated payloads. Beyond cancer therapy, cubosomes have demonstrated effectiveness in wound healing, antibacterial treatments, and various dermatological applications. In the article, the authors provide an overview of the evolution of lipidic nanocarriers, spanning from conventional liposomes to solid lipid nanoparticles, with a special emphasis on the development and applications of cubosomes. Additionally, it delves into recent applications and pre-clinical trials associated with cubosome formulations, which could be of significant interest to readers from backgrounds in nanomedicine and clinicians.

Chemistry

What problem does this paper attempt to address?

This paper focuses on the development of lipid-based nanocarriers, specifically the evolution from liposomes to cubosomes, and their cutting-edge progress in biomedical applications. Traditional liposomes face challenges in drug delivery, such as poor stability, premature drug release, and low loading efficiency. To address these issues, researchers have developed solid lipid nanoparticles (SLNs) and liquid lipid nanoparticles (LLNs), with cubosomes being the third generation of lipid-based nanocarriers, which have attracted extensive attention due to their porous structure, high encapsulation efficiency, enhanced stability, and biocompatibility.

Due to their unique internal structure, cubosomes have the ability to simultaneously carry both water-soluble and lipid-soluble drugs, making them promising in cancer treatment, wound healing, antimicrobial therapy, and dermatological applications. Additionally, cubosomes have shown improvement in gene delivery for cancer treatments, such as RNA interference and gene editing, as they effectively encapsulate and protect nucleic acids, thereby enhancing delivery efficiency to target cells.

This paper reviews the development of lipid-based nanocarriers from initial liposomes to SLNs, and finally cubosomes. It extensively discusses various preparation methods and the advantages of cubosomes in drug delivery systems. The authors also provide examples of liposomal drugs in clinical trials and discuss the contribution of cubosomes in overcoming the limitations of traditional liposomes.

In conclusion, this paper addresses the question of how to improve the performance of drug delivery systems by developing novel lipid-based nanocarriers, particularly cubosomes, to enhance efficacy and reduce side effects, specifically in cancer treatments and other medical applications.